Caroline Helwick

Based on the phase III CLL17 trial, a fixed duration of targeted treatment demonstrated noninferiority to continuous treatment with respect to progression-free survival in previously untreated patients with chronic lymphocytic leukemia (CLL). The findings were presented at the Plenary Session of the 2025 American Society of Hematology (ASH) Annual Meeting & Exposition and simultaneously published in The New England Journal of Medicine. 1,2

For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being paired with the commonly used JAK inhibitor ruxolitinib, as reflected by a wealth of studies presented at the 2025 ASH Annual Meeting & Exposition. Here is a sampling of what The ASCO Post found interesting in this disease area.

Adding hormone therapy to postprostatectomy radiotherapy may provide little survival benefit for most men with prostate cancer, especially those with very low prostate-specific antigen (PSA) levels be...

For years, the question of pregnancy after, or during treatment for, hormone receptor–positive breast cancer placed patients and their oncologists in an uncomfortable position. Endocrine therapy, prescribed for 5 years and increasingly for 10 years or longer in high-risk patients, is both a cornerstone of treatment and a formidable obstacle for young women who have not yet completed their families. The “clinical conundrum” has been real, the data limited, and the guidance largely cautious, says

For years, the question of pregnancy after, or during treatment for, hormone receptor–positive breast cancer placed patients and their oncologists in an uncomfortable position. Endocrine therapy, pres...

Trastuzumab deruxtecan (T-DXd) has claimed a large share of the HER2-positive breast cancer landscape, even finding room among tumors previously thought to be HER2-negative. The DESTINY series of trials are international studies investigating T-DXd as a potential treatment option for eligible patients with certain cancers, including breast, gastric, lung, and other cancer types. Among these trials, there are two in particular that cause clinicians to wonder which approach demonstrates the optimal use of T-DXd in patients with breast cancer.DESTINY-Breast05 1 tested T-DXd in the adjuvant setting in patients with residual disease after neoadjuvant therapy, and DESTINY-Breast11 2 examined its benefit in the neoadjuvant setting.

The treatment landscape for advanced pancreatic cancer is experiencing a tectonic shift. The common RAS mutation is now targetable and the race for the most effective inhibitor is heating up.

Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer improves patient outcomes. Clinicians should therefore proceed with caution until such evidence emerges, according to Heather A. Parsons, MD, MPH, Program Head of Breast Oncology, Associate Professor and Maudslien Endowed Chair in Breast Cancer Precision Oncology Research at the Fred Hutch Cancer Center and University of Washington, Seattle.

In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alone. Interim results from the CLIMATE study found post-orchiectomy Plasma miR-371a-3p (miR-371), a measure of measurable residual disease (MRD), to be superior to existing biomarkers of recurrence. The prospective cohort trial enrolled 200 patients across Australia and New Zealand, and the findings were presented at the 2026 ASCO Genitourinary Cancers Symposium. 1

With recent data that RAS inhibition can improve survival in metastatic pancreatic cancer, 1 the optimization of these agents has become a research priority. Minh Than, MD, PhD, a clinical and research fellow in Hematology-Oncology at Penn Medicine and colleagues have proposed an unorthodox approach: giving these drugs before cancer develops—a concept called “interception.”